Login
$ATYR
$5.24 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Sanjay S. Shukla, M.D., M.S. Also a director
President, Chief Executive Officer and Director
54 Not stated $3,456,253
Jill M. Broadfoot
Chief Financial Officer
64 Since 2018
8 years
$1,309,913
Brandon Yaras
Chief Financial Officer
Title from the Form 4 dated Oct 1, 2026
Not stated Not stated Not reported
Nancy E. Denyes
General Counsel and Corporate Secretary
58 Not stated $1,284,841

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
8.6 years
from year joined
CEO also chairs the board
No
Timothy P. Coughlin
Director On board Independent Committees Other public boards 2025 pay Source
Timothy P. Coughlin
2017
9 years
Independent
Audit Committee
Travere Therapeutics, Inc., ADC Therapeutics SA $194,285
Sanjay S. Shukla
2017
9 years
Not independent None stated None stated Paid as CEO
Eric Benevich
2024
2 years
Independent
Audit Committee Compensation Committee
None stated $163,849
Jane A. Gross
2019
7 years
Independent
Nominating and Corporate Governance Committee
BriaCell Therapeutics Corp. Not stated
Svetlana Lucas
2019
7 years
Independent
Nominating and Corporate Governance Committee
Jasper Therapeutics, Inc. Not stated
Sara L. Zaknoen
2021
5 years
Independent
Compensation Committee
None stated $167,422
Paul Schimmel Leaving at the meeting
2005
21 years
Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Mar 26, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support